Fulltext

Treatment and timing in invasive mould disease

Maertens, Johan ; Groll, Andreas H. ; Cordonnier, Catherine ; de la Cámara, Rafael ; Roilides, Emmanuel ; Marchetti, Oscar

In: Journal of Antimicrobial Chemotherapy, 2011, vol. 66, p. i37-i43

Add to personal list
    Title
    • Treatment and timing in invasive mould disease
    Author
    • Maertens, Johan. Department of Hematology, Acute Leukemia and Stem Cell Transplantation Unit, University Hospitals Leuven, Campus Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium
    • Groll, Andreas H.. Infectious Disease Research Program, Center for Bone Marrow Transplantation and Department of Pediatric Hematology/Oncology, University Children's Hospital Münster, Münster, Germany
    • Cordonnier, Catherine. Service d'Hématologie and Faculté de Médecine, Assistance Publique-Hôpitaux de Paris, Hôpital Henri Mondor, Paris 12, France
    • de la Cámara, Rafael. Haematology Department, Hospital de la Princesa, Madrid, Spain
    • Roilides, Emmanuel. Third Pediatric Department, Aristotle University, Hippokration Hospital, Thessaloniki, Greece
    • Marchetti, Oscar. Infectious Diseases Service, Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Document Type
    • Postprint
    Language
    • English
    Published in
    • Journal of Antimicrobial Chemotherapy, 2011, vol. 66, p. i37-i43. Oxford University Press
    Other Version
    OAI-PMH Identifier
    • oai:doc.rero.ch:299801
    Summary
    Invasive mould disease is a growing threat for immunocompromised patients. The optimum time to use mould-active antifungal agents is much debated. Current approaches to antifungal prophylaxis, early treatment (empirical and pre-emptive therapy) and treatment of documented mould infections in onco-haematology patients are discussed